Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects
Authors:
Open Access
- 7 August 2014
- journal article
- clinical trial
- Published by American Diabetes Association in Diabetes Care
- Vol. 37 (9) , 2609-2615
Abstract
OBJECTIVE We evaluated the endogenous glucose production (EGP) and glucose disposal rate (GDR) over a range of doses of basal insulin peglispro (BIL) and insulin glargine in healthy subjects. RESEARCH DESIGN AND METHODS This was a single-center, randomized, open-label, four-period, incomplete-block, crossover study conducted in eight healthy male subjects. Subjects had 8-h euglycemic clamps performed with primed, continuous infusions of BIL (5.1 to 74.1 mU/min) in three dosing periods and insulin glargine (20 or 30 mU/m2/min) in a fourth period, targeted to achieve 50–100% suppression of EGP. D-[3-3H] glucose was infused to assess rates of glucose appearance and disappearance. RESULTS Mean BIL and insulin glargine concentrations (targeted to reflect the differences in intrinsic affinities of the two basal insulins) ranged from 824 to 11,400 and 212 to 290 pmol/L, respectively, and increased accordingly with increases in dose. Suppression of EGP and stimulation of GDR were observed with increasing concentrations of both insulins. At insulin concentrations where EGP was significantly suppressed, insulin glargine resulted in increased GDR. In contrast, at comparable suppression of EGP, BIL had minimal effect on GDR at lower doses and had substantially less effect on GDR than insulin glargine at higher doses. CONCLUSIONS The novel basal insulin analog BIL has relative hepatopreferential action and decreased peripheral action, compared with insulin glargine, in healthy subjects.Keywords
This publication has 30 references indexed in Scilit:
- Insulin effects in muscle and adipose tissueDiabetes Research and Clinical Practice, 2011
- Minimal model assessment of hepatic insulin extraction during an oral test from standard insulin kinetic parametersAmerican Journal of Physiology-Endocrinology and Metabolism, 2009
- Pulsatile Insulin Secretion Dictates Systemic Insulin Delivery by Regulating Hepatic Insulin Extraction In HumansDiabetes, 2005
- Inhalation of Insulin in DogsDiabetes, 2004
- Kinetics of circulating endogenous insulin, C-peptide, and proinsulin in fasting nondiabetic manMetabolism, 1987
- Hepatic Removal of Insulin in Normal Man: Dose Response to Endogenous Insulin Secretion*The Journal of Clinical Endocrinology & Metabolism, 1983
- Splanchnic and renal metabolism of insulin in human subjects: a dose-response studyAmerican Journal of Physiology-Endocrinology and Metabolism, 1983
- “Normal” Insulin Secretion: The Goal of Artificial Insulin Delivery Systems?Diabetes Care, 1980
- Effect of Renal Disease on Renal Uptake and Excretion of Insulin in ManNew England Journal of Medicine, 1970
- STUDIES ON TISSUE UPTAKE OF INSULIN IN MAN USING A DIFFERENTIAL IMMUNOASSAY FOR ENDOGENOUS AND EXOGENOUS INSULIN*Journal of Clinical Investigation, 1961